Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Tobii AB (publ) in connection with its rights issue
Mandate

Vinge has advised Tobii AB (publ) in connection with its rights issue

April 03, 2024 Capital Markets and Public M&A

Vinge has advised Tobii AB (publ) in connection with a fully guaranteed rights issue of ordinary shares which will provide Tobii with issue proceeds of approximately SEK 301 million before deduction of transaction costs.

The new ordinary shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 15 April 2024. Tobii develops technology within eye tracking and attention computing which understands human attention and intent. Tobii’s eye tracking solutions are used by thousands of enterprises, universities and research institutes around the globe. The company's ordinary shares are listed on Nasdaq Stockholm.

 

Vinge’s team consisted primarily of Jesper Schönbeck, Rikard Lindahl, Amanda Knutsson, Joel Magnusson, Oskar Nilsson, Lorin Arabi, Elias Kröger, Lovisa Jonassen och William Carlberg Johansson.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026